Moderna: Massive Asymmetry About What The mRNA Is! (NASDAQ:MRNA)
· seekingalpha.com
Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.
On August 19, Merck and Moderna ( MRNA ) announced that their phase 3 melanoma study had met both of its efficacy endpoints. Although we do not have the actual ...